Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Complete Title: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).
Trial Phase: II/III
Investigator: Christina Baik
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Keywords:
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Carcinoma, Bronchogenic
- Neoplasms, Bronchial
- Neoplasms, Thoracic
- Respiratory Tract Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II/III
Christina Baik
RG1004973
NCT03851445
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).
Lung Carcinoma, Non-Small-Cell (NSCLC)
Carcinoma, Bronchogenic
Neoplasms, Bronchial
Neoplasms, Thoracic
Respiratory Tract Diseases